Chord Therapeutics ^Company

Chord Therapeutics is a pharmaceutical company that focuses on developing drugs for patients suffering from rare, life-threatening, and severely disabling diseases. They are currently working on their lead drug candidate CRD1, which is being developed for the treatment of neuromyelitis optica spectrum disorders and myasthenia gravis. The company was founded in 2014 and is headquartered in Geneva, Switzerland.